UroGen Pharma (URGN) Asset Utilization Ratio (2018 - 2026)
UroGen Pharma's (URGN) quarterly Asset Utilization Ratio came in at 0.62 in Q1 2026, up 79.59% YoY from 0.34 in Q1 2025, and up 8.63% on a QoQ basis from 0.57 in Q4 2025.
UroGen Pharma (URGN) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 9 years of Asset Utilization Ratio data on file, last reported at 0.62 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 79.59% year-over-year to 0.62 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.62 (up 79.59% YoY) and the FY2025 annual result came in at 0.45, up 15.92% from the prior year.
- Asset Utilization Ratio grew to 0.62 in Q1 2026, from 0.57 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.7 in Q2 2023 to a low of 0.31 in Q3 2024.
- A 5-year average of 0.46 and a median of 0.45 in 2024 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio soared 115.72% — and 2024, when it tumbled 49.38%.
- Tracing URGN's Asset Utilization Ratio over 5 years: stood at 0.49 in 2022, then slipped by 8.75% to 0.44 in 2023, then sank by 30.83% to 0.31 in 2024, then surged by 85.14% to 0.57 in 2025, then increased by 8.63% to 0.62 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.62 (Q1 2026), 0.57 (Q4 2025), and 0.49 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.75 |
| Mar 31, 2026 | 0.62 |
| Dec 31, 2025 | 0.57 |
| Sep 30, 2025 | 0.49 |
| Jun 30, 2025 | 0.41 |
| Mar 31, 2025 | 0.34 |
| Dec 31, 2024 | 0.31 |
| Sep 30, 2024 | 0.31 |
| Jun 30, 2024 | 0.35 |
| Mar 31, 2024 | 0.45 |
| Dec 31, 2023 | 0.44 |
| Sep 30, 2023 | 0.53 |
| Jun 30, 2023 | 0.70 |
| Mar 31, 2023 | 0.55 |
| Dec 31, 2022 | 0.49 |
| Sep 30, 2022 | 0.45 |
| Jun 30, 2022 | 0.37 |
| Mar 31, 2022 | 0.38 |
| Dec 31, 2021 | 0.38 |
| Sep 30, 2021 | 0.28 |